# Effect of PP-01 on Cannabis Withdrawal Syndrome

> **NCT05494437** · PHASE2 · COMPLETED · sponsor: **PleoPharma, Inc.** · enrollment: 234 (actual)

## Conditions studied

- Cannabis Withdrawal

## Interventions

- **COMBINATION_PRODUCT:** PP-01 High Dose
- **COMBINATION_PRODUCT:** PP-01 Low Dose
- **DRUG:** Placebo
- **DRUG:** Nabilone
- **DRUG:** Gabapentin

## Key facts

- **NCT ID:** NCT05494437
- **Lead sponsor:** PleoPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-27
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-21
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494437, "Effect of PP-01 on Cannabis Withdrawal Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05494437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*